Abstract
Perspectives of patients with fibromyalgia influence their likelihood of participating in randomized placebo-controlled trials and potentially clash with current, well-established methodology of randomized controlled trial design. Mandates to use only acetaminophen for breakthrough pain and that require discontinuation of concomitant medications, especially in studies lacking an active comparator arm, could bias a trial cohort to thereby reduce the generalizability of study findings and conclusions. This study evaluates factors affecting willingness to participate in such clinical trials, including the impact of altruism, payment, study duration, forced discontinuation of specific medications, and subject demographics for patients seen by rheumatologists proficient and avidly interested in treating fibromyalgia.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Papers of particular interest, published recently, have been highlighted as: •• Of major importance
Russell IJ, Vaeroy H, Javors M, Nyberg F: Cerebrospinal fluid biogenic amine metabolites in fibromyalgia/fibrositis syndrome and rheumatoid arthritis. Arthritis Rheum 1992, 35:550–556.
Wood PB: Mesolimbic dopaminergic mechanisms and pain control. Pain 2006, 120:230–234.
Mease PJ: Further strategies for treating fibromyalgia: the role of serotonin and norepinephrine reuptake inhibitors. Am J Med 2009, 122(12 Suppl):S44–S55.
Lentz MJ, Landis CA, Rothermel J, Shaver JL: Effects of selective slow wave sleep disruption on musculoskeletal pain and fatigue in middle aged women. J Rheumatol 1999, 26:1586–1592.
Moldofsky H, Scarisbrick P, England R, Smythe H: Musculoskeletal symptoms and non-REM sleep disturbance in patients with “fibrositis syndrome” and healthy subjects. Psychosom Med 1975, 37:341–351.
Moldofsky H, Scarisbrick P: Induction of neurasthenic musculoskeletal pain syndrome by selective sleep stage deprivation. Psychosom Med 1976, 38:35–44.
MacFarlane JG, Shahal B, Mously C, Moldofsky H: Periodic K-alpha sleep EEG activity and periodic limb movements during sleep: comparisons of clinical features and sleep parameters. Sleep 1996, 19:200–204.
Martinez-Lavin M: Biology and therapy of fibromyalgia. Stress, the stress response system, and fibromyalgia. Arthritis Res Ther 2007, 9:216.
Martínez-Lavín M, Hermosillo AG: Autonomic nervous system dysfunction may explain the multisystem features of fibromyalgia. Semin Arthritis Rheum 2000, 29:197–199.
Petzke F, Clauw DJ: Sympathetic nervous system function in fibromyalgia. Curr Rheumatol Rep 2000, 2:116–123.
•• Yunus MB: Role of central sensitization in symptoms beyond muscle pain, and the evaluation of a patient with widespread pain. Best Pract Res Clin Rheumatol 2007, 21:481–497. This article reviews proposed mechanisms that perpetuate and intensify the complex fibromyalgia experience.
Staud R, Robinson ME, Price DD: Temporal summation of second pain and its maintenance are useful for characterizing widespread central sensitization of fibromyalgia patients. J Pain 2007, 8:893–901.
Lee SJ, Lenert L, Weisman S, Kavanaugh A: Factors affecting rheumatoid arthritis patients’ decisions to participate in clinical trials. J Rheumatol 2005, 32:2317–2325.
Koehn CL: The role of ethnicity in willingness to participate in rheumatoid arthritis trials. J Rheumatol 2005, 32:2283–2284.
Bird HA: Patient confidence in clinical trials. J Rheumatol 2005, 32:2281–2282.
Disclosures
No potential conflicts of interest relevant to this article were reported.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Holman, A.J., Neradilek, M.B., Dryland, D.D. et al. Patient-derived Determinants for Participation in Placebo-controlled Clinical Trials for Fibromyalgia. Curr Pain Headache Rep 14, 470–476 (2010). https://doi.org/10.1007/s11916-010-0152-4
Published:
Issue Date:
DOI: https://doi.org/10.1007/s11916-010-0152-4